市場調查報告書
商品編碼
1418732
全球 3D 列印生物材料墨水市場 - 2023-2030Global 3D Printable Biomaterial Ink Market - 2023-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
全球3D列印生物材料墨水市場在2022年達到5.687億美元,預計到2030年將達到22.563億美元,2023-2030年預測期間CAGR為18.8%。
隨著 3D 列印植入物在骨科和矯正領域變得越來越普遍,全球 3D 列印生物材料墨水市場正在重新擴張。 3D列印牙科和骨科植入物已成為治療各種疾病的標準,從而為生物材料墨水提供了穩定的需求來源。
全球 3D 列印生物材料墨水市場的長期成長潛力因過去幾年新創新和產品發布步伐的放緩而受到阻礙。如果沒有新的創新來滿足再生醫學和生物植入領域即將取得的突破,全球市場將面臨成長停滯的風險。
近年來,再生醫學取得了許多重要突破,這主要歸功於廣泛的國際合作。從新的生物材料到新的治療劑,許多新的再生療法預計將在未來幾年投放市場。所有這些進步都可能在中長期轉化為 3D 列印生物材料墨水的新需求成長。
由於其已有的新聞,水凝膠已成為一個特別關注的領域,使其成為 3D 列印應用的理想選擇。例如,根據中國上海交通大學第六人民醫院科學家發表的一篇研究論文,水凝膠適合用於複雜多組織植入物的受控3D列印。
幹細胞療法是另一個正在積極研究的主要領域,特別是因為它在治療心臟病方面很有前景。美國主要醫院和研究中心梅奧診所於 2023 年 12 月發表的新研究發現,新的幹細胞療法可顯著改善晚期心臟衰竭患者的生活品質。
由於需要減少傳統肉類產業所需的土地和水資源,實驗室種植的 3D 列印肉類成為了部分科技創業家的流行想法。然而,這個不起眼的想法現在引起了主流關注,許多新創公司都致力於開發實驗室培育的肉類。
例如,2023 年 6 月,美國食品藥物管理局 (USFDA) 宣布監管部門批准 GOOD Meat 和 UPSIDE Foods 兩家新創公司在美國市場銷售實驗室培育的雞肉。此外,2023 年 12 月,以色列新創公司 Steakholder 宣布開發出新型 3D 列印實驗室培育鰻魚肉。
生物材料墨水是實驗室培育肉類的重要組成部分,在列印過程中墨水用作黏合劑和填充劑。實驗室培育的肉類日益普及,將使墨水製造商能夠開發出更適合不同肉類類型的新型食用墨水,從而促進全球市場的成長。
使用3D列印生物材料墨水的新興領域,如再生醫學和生物植入,歷來有很長的醞釀期。創造一個全新的突破性創新需要數年甚至數十年的時間。此外,產品獲准在市場上銷售之前還需要獲得一系列主要監管部門的批准。
這一直是阻礙全球市場成長潛力的持續因素。由於新產品偶爾會上市,因此可列印生物材料墨水的需求沒有大幅擴大的空間。此外,需求在大部分時間裡仍然停滯不前,阻礙了生物材料油墨製造商投資產能擴張。
Global 3D Printable Biomaterial Ink Market reached US$ 568.7 million in 2022 and is expected to reach US$ 2,256.3 million by 2030, growing with a CAGR of 18.8% during the forecast period 2023-2030.
The global 3D printable biomaterial ink market is setting for renewed expansion as 3D printed implants become increasingly common in orthopedics and orthodontics. 3D Printed dental and orthopedic implants have become standard for the treatment of various ailments, thus providing a steady source of demand for biomaterial ink.
The long term growth potential for the global 3D printable biomaterial ink market is hobbled by declining pace of new innovation and product launches over the past few years. Without new innovations catering to the up and coming breatkthroughs in regenerative medicines and bio implants, the global market faces a risk of stagnating growth.
Regenerative medicine has witnessed several important breakthroughs in recent years, mainly due to extensive international collaboration. From new bio materials to new therapeutic agents, many new regenerative treatments are expected to hit the market during the upcoming years. All these advances are likely to translate into renewed demand growth for 3D printable biomaterial ink over the medium and long term.
Hydrogels have become a particular area of focus, due to their pre-existing news, making them ideal for 3D printing applications. For instance, according to a research paper published by scientists from the Sixth People's Hospital, Shanghai JiaoTong University in China, hydrogels are suitable for controlled 3D printing for complex multi-tissue implants.
Stem cell therapy is another major area that is actively researched, especially due to its promising approach towards the treatment of heart diseases. New research published in December 2023, by the Mayo Clinic, a major U.S.-based hospital and research center, found that new stem cell therapy significantly improved quality of life for patients with advanced heart failure.
Driven by the need to reduce land and water resources required for the convetional meat industry, lab grown, 3D printed meat was a popular idea adopted by a section of tech entrepreneurs. However, this obscure idea has now attracted mainstream attention and many startups are engaged in developing lab grown meat.
For instance, in June 2023, U.S. food and drug administration (USFDA) announced that it had given regulatory approval to two startups, GOOD Meat and UPSIDE Foods, to sell lab grown chicken meat in U.S. market. Furthermore, in December 2023, Steakholder, an Israeli startup, announced the development of its new 3D printed, lab grown eel meat.
Biomaterial ink is an important component of lab grown meat, where the ink is used as a binder and a filler during the printing process. The growing popularity of lab grown meat will allow ink manufacturers to develop new types of edible ink more suitable for different meat types, thus contributing to the growth of the global market.
The emerging fields in which 3D printable biomaterial ink is used such as regenerative medicine and bio implants, have historically had long gestation periods. It takes years, if not decades to create a fundamentally new breakthrough innovation. Furthermore, there are a string of major regulatory approvals that are required before the products are allowed to be sold in the market.
It has been a consistent factor in hobbling the growth potential of the global market. Since a new product only comes on the market once in a while, there is no scope for radical expansion of demand for printable biomaterial ink. Furthermore, demand continues to remain stagnant for most of the time, disincentivizing biomaterial ink manufacturers from investing in capacity expansion.
The global 3D printable biomaterial ink market is segmented based on type, application and region.
Biomedical implants are witnessing radical new innovations and could potentially generate the highest demand for printable biomaterial ink during the forecast period. One of the key advantages of bio implants is that there is low risk of implant rejection and low immunogenicity. Furthermore, depending on the requirement, the bio implant can remain within the patient's body permanently or undergo biodegradation without any risk to the patient's health.
Current biomedical research is focused on expanding the type and materials of bio implants as well as improving the overall process for bio implant manufacturing. As numerous patents get filed and regulatory approvals are obtained, the demand for printable biomaterial inks for implant manufacturing will skyrocket over the upcoming years.
North America is expected to have the highest share within the global 3D printable biomaterial ink market since it has the largest share of startups and research institutions focused on researching emerging biomedical breakthroughs. All of this is made possible by the well-ordained research-oriented academic ecosystem of U.S. universities. Furthermore, many venture capital funds and government agencies generously fund research in hopes of commercializing new breakthroughs.
Several new 3D bio implants have received regulatory approval over the course of 2023 and the future demand for printable biomaterial ink appears to be stable. For instance, in December 2023, U.S. food and drug administration (USFDA) approved Novosis Ortho, a new, 3D printed spine implant designed to accelerate bone recovery in the event of a spinal injury.
Companies are already entering into collaborative partnerships to help develop this emerging market. For instance, in April 2023, Stratasys, a 3D printing solutions provider, signed a partnership agreement with CollPlant, an Israeli-American company specializing in regenerative medicine, to develop 3D printed regenerative breast implants.
The COVID-19 pandemic created several pitfalls and challenges for the global 3D printable biomaterial ink market. First and foremost, the imposition of lockdowns during the initial pandemic period disrupted research work, forcing many companies to delay and extend the launch of new products. Furthermore, uncertainty in global markets prompted many companies to abandon strenuous research areas. A stark reduction in venture capital funding also led to the bankruptcy of some emerging startups.
The difficult market conditions also created many problems for the supply of 3D printable biomaterial ink. Due to its specialist and niche nature, production was already limited before the pandemic and was further restricted since precursor materials were in short supply due to pandemic induced supply chain disruptions. The overall situation has improved in the post-pandemic period; however, the market is still likely to face challenges over the short and medium term.
The Russia-Ukraine will not significantly impact the global 3D printable biomaterial ink market at large. Although the war did cause major short-term volatility in global energy markets due to severe economic sanctions on Russia, the volatility has been priced in and is unlikely to generate major concern. A temporary spike in precursor material prices led to slightly elevated prices for 3D printable biomaterial ink in the short term.
The most direct impact has been on the local 3D printable biomaterial ink markets in Ukraine and Russia. Many Ukrainian scientists fled the war and have continued their research from universities and research institutes in western Europe. Economic sanctions have led to the cessation of exports of biomaterial ink to Russian entities.
However, some Russian institutions have purchased stocks from Chinese suppliers and the grey market to continue research. Many Russian scientists opposing the war have also fled Russia, thus hobbling the long term growth potential of the domestic market due to loss of talented human capital.
The major global players in the market include: 3D Systems, Inc., Stratasys, Evonik Industries AG, Renishaw plc., Formlabs, Envisiontec US LLC, Sandvik AB, EOS, Aspect Biosystems Ltd. and Bio Inx.
The global 3D printable biomaterial ink market report would provide approximately 46 tables, 41 figures and 187 Pages.
LIST NOT EXHAUSTIVE.